FAERS Analyses Uncover Diverse Drug Safety Risks Across Therapeutic Areas
Recent studies using FDA Adverse Event Reporting System data have identified drug-associated cardiovascular risks, pediatric dry eye, and venlafaxine adverse effects. Findings highlight the importance of pharmacovigilance monitoring.